JP2025516543A5 - - Google Patents
Info
- Publication number
- JP2025516543A5 JP2025516543A5 JP2024566197A JP2024566197A JP2025516543A5 JP 2025516543 A5 JP2025516543 A5 JP 2025516543A5 JP 2024566197 A JP2024566197 A JP 2024566197A JP 2024566197 A JP2024566197 A JP 2024566197A JP 2025516543 A5 JP2025516543 A5 JP 2025516543A5
- Authority
- JP
- Japan
- Prior art keywords
- egfr inhibitor
- combination
- independently selected
- combination according
- heterocycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22173211.8 | 2022-05-13 | ||
| EP22173211 | 2022-05-13 | ||
| EP22175302 | 2022-05-25 | ||
| EP22175302.3 | 2022-05-25 | ||
| PCT/EP2023/062530 WO2023217924A1 (en) | 2022-05-13 | 2023-05-11 | Combination of allosteric and orthosteric egfr inhibitors for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025516543A JP2025516543A (ja) | 2025-05-30 |
| JP2025516543A5 true JP2025516543A5 (enExample) | 2026-05-18 |
Family
ID=86558741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024566197A Pending JP2025516543A (ja) | 2022-05-13 | 2023-05-11 | がんの治療のためのアロステリックおよびオルソステリックｅｇｆｒ阻害剤の組み合わせ |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20260007678A1 (enExample) |
| EP (1) | EP4522113A1 (enExample) |
| JP (1) | JP2025516543A (enExample) |
| KR (1) | KR20250009977A (enExample) |
| CN (1) | CN119173253A (enExample) |
| AU (1) | AU2023268579A1 (enExample) |
| CA (1) | CA3255503A1 (enExample) |
| TW (1) | TW202408534A (enExample) |
| WO (1) | WO2023217924A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020254565A1 (en) | 2019-06-21 | 2020-12-24 | F. Hoffmann-La Roche Ag | Egfr inhibitors for the treatment of cancer |
| WO2022117475A1 (en) | 2020-12-01 | 2022-06-09 | F. Hoffmann-La Roche Ag | New indazole derivatives |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020254565A1 (en) * | 2019-06-21 | 2020-12-24 | F. Hoffmann-La Roche Ag | Egfr inhibitors for the treatment of cancer |
| WO2022117487A1 (en) * | 2020-12-01 | 2022-06-09 | F. Hoffmann-La Roche Ag | New indazole derivatives |
| US20240002390A1 (en) * | 2020-12-01 | 2024-01-04 | Hoffmann-La Roche Inc. | New indazole acetylene derivatives |
| WO2022117475A1 (en) * | 2020-12-01 | 2022-06-09 | F. Hoffmann-La Roche Ag | New indazole derivatives |
-
2023
- 2023-05-11 US US18/865,274 patent/US20260007678A1/en active Pending
- 2023-05-11 WO PCT/EP2023/062530 patent/WO2023217924A1/en not_active Ceased
- 2023-05-11 CA CA3255503A patent/CA3255503A1/en active Pending
- 2023-05-11 KR KR1020247037653A patent/KR20250009977A/ko active Pending
- 2023-05-11 EP EP23726084.9A patent/EP4522113A1/en active Pending
- 2023-05-11 AU AU2023268579A patent/AU2023268579A1/en active Pending
- 2023-05-11 JP JP2024566197A patent/JP2025516543A/ja active Pending
- 2023-05-11 CN CN202380039827.0A patent/CN119173253A/zh active Pending
- 2023-05-12 TW TW112117726A patent/TW202408534A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220241261A1 (en) | Combinations of inhibitors of irak4 with inhibitors of btk | |
| EP2101759B1 (en) | Methods of using mek inhibitors | |
| ES2985528T3 (es) | Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de enfermedades | |
| JP2025508703A5 (enExample) | ||
| JP7592689B2 (ja) | Ｓｔｉｎｇアゴニストとしての大環状化合物並びにその方法及び使用 | |
| JP6537527B2 (ja) | Ｊａｋ及びｐｉ３ｋ阻害剤併用によるｂ細胞悪性腫瘍の処置 | |
| WO2024229447A1 (en) | Pyrido[4,3-d]pyrimidine derivatives as mutant kras g12c inhibitors for the treatment of cancer | |
| RU2472509C2 (ru) | Способ лечения артрита | |
| JP2020510015A5 (enExample) | ||
| JP2021519775A5 (enExample) | ||
| JP2012524053A5 (enExample) | ||
| JP2005538099A5 (enExample) | ||
| JP2020510010A5 (enExample) | ||
| IL279800B1 (en) | Selective allosteric inhibitors of epidermal growth factor receptor mutants, pharmaceutical preparations containing them and their use | |
| JP2013520420A5 (enExample) | ||
| JP2022513409A5 (enExample) | ||
| JP2023550902A5 (enExample) | ||
| JP2013522372A5 (enExample) | ||
| JP2012508239A (ja) | Ｐ７０ｓ６キナーゼ阻害剤およびｍｔｏｒ阻害剤の併用療法 | |
| JP2024516430A5 (enExample) | ||
| JP2009500366A5 (enExample) | ||
| RU2024137254A (ru) | Комбинация аллостерических и ортостерических ингибиторов egfr для лечения рака | |
| JP2025515051A (ja) | 重水素化ｊａｋ阻害剤による治療のための投与レジメン | |
| JP2024529485A (ja) | イミダゾ［１，２－ｂ］ピリダジニル化合物及びその使用 | |
| WO2018186366A1 (ja) | 新規サイクリン依存性キナーゼ８及び／又は１９阻害剤 |